Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

CB-103

CB-103 + lenvatinib or abemaciclib

Cellestia Biotech · Phase 1/2 · Recruiting · Enrollment 32

NCT05774899

Catalyst Primary completion. 06.01.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.